JP Morgan Chase
CMPX icon

JP Morgan Chase’s Compass Therapeutics CMPX Stock Holding History

JP Morgan Chase’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.32M Sell
847,702
-22,312
-3% -$129K ﹤0.01% 3456
2025
Q4 		$4.67M Sell
870,014
-1,129,264
-56% -$5.21M ﹤0.01% 3372
2025
Q3 		$7M Sell
1,999,278
-126,439
-6% -$399K ﹤0.01% 3061
2025
Q2 		$5.53M Sell
2,125,717
-59,763
-3% -$123K ﹤0.01% 3062
2025
Q1 		$4.15M Buy
2,185,480
+1,913,152
+703% +$5.09M ﹤0.01% 3319
2024
Q4 		$395K Buy
272,328
+227,864
+512% +$378K ﹤0.01% 5159
2024
Q3 		$81.8K Sell
44,464
-1,419
-3% -$1.77K ﹤0.01% 5777
2024
Q2 		$45.9K Buy
45,883
+7,530
+20% +$11K ﹤0.01% 5890
2024
Q1 		$75.9K Sell
38,353
-23,979
-38% -$41.4K ﹤0.01% 5784
2023
Q4 		$97.2K Sell
62,332
-407
-0.6% -$704 ﹤0.01% 5743
2023
Q3 		$124K Sell
62,739
-8,425
-12% -$20.8K ﹤0.01% 5351
2023
Q2 		$226K Buy
71,164
+70,757
+17,385% +$222K ﹤0.01% 5007
2023
Q1 		$1K Buy
+407
New +$1.6K ﹤0.01% 6501
2022
Q1 		– Sell
-23,749
Closed -$75K – 6634
2021
Q4 		$75K Buy
+23,749
New +$78.8K ﹤0.01% 5788

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase's CMPX Position: Q1 2026 in Review

JP Morgan Chase reduced its Compass Therapeutics (CMPX) stake by 2.6% in Q1 2026, selling an estimated $129K and leaving 847,702 shares worth $4.32M. The position accounts for ﹤0.01% of the portfolio, ranked #3456.

JP Morgan Chase first reported a position in CMPX in Q4 2021 and has held it in 14 quarters since. The position peaked at $7M in Q3 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • JP Morgan Chase held 847,702 shares of Compass Therapeutics worth $4.32M as of Q1 2026.
  • JP Morgan Chase sold 22,312 Compass Therapeutics shares in Q1 2026, an estimated $129K.
  • Compass Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3456 holding.
  • JP Morgan Chase first reported a position in Compass Therapeutics in Q4 2021 and has held it in 14 quarters since.
  • JP Morgan Chase's Compass Therapeutics position peaked at $7M in Q3 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.